Name: Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPAC Name

(4S)-4-[(2-aminoacetyl)amino]-5-[3-[[4-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-8-(2-phosphonooxyacetyl)-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-6-yl]phenyl]methyl]anilino]-5-oxopentanoic acid;2,2,2-trifluoroacetic acid

Canonical SMILES

CC12CC(C3C(C1CC4C2(OC(O4)C5=CC=C(C=C5)CC6=CC(=CC=C6)NC(=O)C(CCC(=O)O)NC(=O)CN)C(=O)COP(=O)(O)O)CCC7=CC(=O)C=CC37C)O.C(=O)(C(F)(F)F)O

InChI

InChI=1S/C42H50N3O13P.C2HF3O2/c1-40-15-14-28(46)18-26(40)10-11-29-30-19-34-42(33(48)22-56-59(53,54)55,41(30,2)20-32(47)37(29)40)58-39(57-34)25-8-6-23(7-9-25)16-24-4-3-5-27(17-24)44-38(52)31(12-13-36(50)51)45-35(49)21-43;3-2(4,5)1(6)7/h3-9,14-15,17-18,29-32,34,37,39,47H,10-13,16,19-22,43H2,1-2H3,(H,44,52)(H,45,49)(H,50,51)(H2,53,54,55);(H,6,7)/t29-,30-,31-,32-,34+,37+,39+,40-,41-,42+;/m0./s1

InChIKey

NOBUOSRJAGZZDD-JQUJFOOXSA-N

Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA is a compound with significant potential in the field of anti-inflammatory therapies. This compound is designed to specifically activate the glucocorticoid receptor (GR), a key mediator in the body’s response to stress and inflammation. By binding to this receptor, the compound can mimic the effects of natural glucocorticoids, such as cortisol, which are used to reduce inflammation in conditions like rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD). The ability to modulate the glucocorticoid receptor’s activity offers a pathway for developing more targeted anti-inflammatory treatments with potentially fewer side effects compared to traditional corticosteroid therapies.

Another important application of Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA is in the modulation of immune responses. Glucocorticoid receptor agonists have been shown to have potent immunosuppressive effects, which can be advantageous in managing autoimmune diseases where the immune system mistakenly attacks the body’s own tissues. By specifically targeting the glucocorticoid receptor, this compound could help to suppress overactive immune responses in conditions such as lupus, multiple sclerosis, or psoriasis. This selective activation helps achieve therapeutic benefits while minimizing broader immune system suppression, which can lead to increased susceptibility to infections.

In addition to its therapeutic uses, Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA is also being studied for its role in enhancing the efficacy of other treatments, such as cancer immunotherapy. Recent research suggests that glucocorticoid receptor agonists can improve the effectiveness of certain cancer therapies by modulating the tumor microenvironment. By reducing inflammation and suppressing immune cell infiltration into tumors, these agonists could potentially make tumors more susceptible to chemotherapy, targeted therapy, or immunotherapy. As a result, this compound could become an important adjuvant in cancer treatment regimens.